[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glioma-any-grade-in-the-brain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glioma-any-grade-in-the-brain":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100637689","brain-connectivity-changes-in-glioma-patients-during-treatment-100637689",false,"NCT07612917","Brain Connectivity Changes in Glioma Patients During Treatment","Functional Reorganization and Connectivity in Glioma Patients During the Therapeutic Trajectory","GliRecon","Inclusion Criteria:\n\n* Patients with diffuse gliomas (WHO grade 2-4).\n* Age \\>18 years and \\\u003C65 years.\n* Written participant information and informed consent provided and signed.\n* Signed informed consent for functional magnetic resonance imaging (fMRI).\n\nExclusion Criteria:\n\n* Age \\\u003C18 years or \\>65 years.\n* Pregnancy.\n* Contraindications to MRI, including but not limited to:\n\n  * Active medical implants (e.g., pain pump, defibrillator, cardiac pacemaker),\n  * Orthodontic braces,\n  * Metallic tattoos,\n  * Non-removable piercings,\n  * Known metallic foreign bodies,\n  * Claustrophobia.\n* Cerebral metastases from secondary (non-primary) tumors.\n* Absence of baseline BOLD functional MRI and\u002For baseline neurocognitive assessment.\n* Failure to provide written participant information and informed consent.\n* Karnofsky Performance Status (KPS) \\\u003C60, unless feasibility of clinical-psychological testing and BOLD fMRI is confirmed by the investigator in consultation with clinical psychology, radiology staff, and the patient.","ALL","18 Years","64 Years",{"count":21,"type":22},20,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to better understand how the brain changes during the treatment of glioma. In particular, the study looks at changes in important brain areas that are responsible for functions such as movement, language, or sensation, as well as the nerve fiber pathways that connect these areas.\n\nThe main question this study aims to answer is:\n\nHow do important brain areas and their connections adapt and reorganize over the course of glioma treatment?\n\nPatients with glioma will undergo repeated brain imaging examinations as part of their regular medical care. These images will be analyzed over time to observe changes in brain activity and structure during different stages of therapy.\n\nBy studying these changes, researchers hope to gain new insights into the brain's ability to adapt (neuroplasticity) throughout the entire course of glioma treatment.",[26,27,28,29],"Glioma (Any Grade) in the Brain","Gliomas, Malignant","fMRI Research","Neurocognitive Function",[31,32,33,34,35],"Glioma,","Magnetic Resonance Imaging, Functional","Brain Mapping","Neural Plasticity","Cognition","RECRUITING","2026-05-28",{"date":39,"type":40},"2026-05-29","ACTUAL",{"date":42,"type":22},"2026-05",{"date":44,"type":22},"2029-12",{"name":46,"class":47},"Johannes Kepler University of Linz","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100601093","radiolabeled-tspo-targeted-molecular-probe-in-glioma-100601093","NCT07106008","Radiolabeled TSPO Targeted Molecular Probe in Glioma","Clinical Application of a Novel Radiolabeled Translocator Protein (TSPO) Targeted Small Molecular Probe in Neuroinflammation Imaging of Glioma","Inclusion Criteria:\n\n* Voluntary subjects, patients, or their legal representatives must sign the informed consent form.\n* There are no restrictions on the gender of volunteers; age must be between 18 and 75 years, inclusive.\n* Other imaging examination methods (e.g., CT, MRI) show the presence of intracranial lesions.\n* Patients with brain glioma who are scheduled for surgery or biopsy that will provide final pathological results.\n* Patients must have a kidney GFR \\> 50 mL\u002Fmin, ERPF \\> 280 mL\u002Fmin, platelet count (PLT) \\> 75,000\u002FμL, white blood cell count (WBC) \\> 3,000\u002FμL, and alanine aminotransferase (ALT) and asparta.\n\nExclusion Criteria:\n\n* Individuals with a history of allergy to drugs with similar chemical or biological components to TSPO, a history of atopy, or currently suffering from allergic diseases.\n* Individuals currently participating in other drug clinical studies, or who have previously participated in any drug (excluding vitamins and minerals) clinical studies.\n* Individuals with other difficult-to-control clinical conditions, such as HIV infection, hepatitis C virus infection, active hepatitis B, other severe chronic infections, or serious mental, neurological, cardiovascular, respiratory, or other systemic diseases.\n* Red blood cell count (RBC) \\\u003C 4×10\\^12\u002FL, white blood cell count (WBC) \\\u003C 3×10\\^9\u002FL, hemoglobin \\\u003C 110 g\u002FL, platelet count (PLT) \\\u003C 75×10\\^9\u002FL.\n* Significant liver and kidney function abnormalities, glomerular filtration rate (GFR) \\\u003C 50 ml\u002Fmin.\n* Tumor burden involving more than 50% of the affected organ, or significant spinal cord compression.\n* Expected survival time less than six months, or having received chemotherapy within the past six months.\n* Individuals with severe acute comorbidities or severe refractory mental disorders.\n* Pregnant or breastfeeding women (pregnancy defined as a positive urine pregnancy test).\n* Individuals whose physical condition is unsuitable for radioactive examination.\n* Other circumstances deemed unsuitable for participation in the trial by the investigator.","75 Years",{"count":58,"type":22},8,"Evaluate the clinical application value of the novel radiolabeled TSPO-targeted molecular probe Gallium \\[68Ga\\]-DOTA-HK-011 in inflammation imaging of glioma.",[26],"NOT_YET_RECRUITING","2025-07-30",{"date":64,"type":40},"2025-08-06",{"date":66,"type":22},"2025-09-01",{"date":68,"type":22},"2026-08-31",{"name":70,"class":47},"Nanjing First Hospital, Nanjing Medical University"]